Page 4,883«..1020..4,8824,8834,8844,885..4,8904,900..»

Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I …

Posted: Published on September 26th, 2013

SAN DIEGO, CA--(Marketwired - Sep 26, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today its subsidiary Regen BioPharma Inc. signed an agreement with Dr. Wei-Ping Min covering experiments requested by the FDA in support of clearance for the company's IND #15376 for use of HemaXellerate I in the treatment of drug refractory aplastic anemia. Regen BioPharma filed an Investigational New Drug (IND) application for HemaXellerate I in February 2013 seeking permission from the FDA to initiate a ten patient clinical trial. The FDA reviewed the Company's IND application and had a series of questions, which the company responded to on June 7th. The first series of comments were related to the manufacturing of HemaXellerate I and were successfully addressed. Subsequently the FDA responded with a second series of comments relating to cellular responses in mouse models of aplastic anemia. Regen BioPharma has been in discussions with Dr. Wei-Ping Min, who also sits on the company's scientific advisory board regarding responding to the FDA comments. On September 24th, Dr. Min signed a services agreement for conducting the animal studies requested by the FDA. "Having worked in an advisory capacity with Regen BioPharma for more than a year now, I … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I …

Joseph Purita, M.D. and Maritza Novas, R.N., M.S.N of Stem Cell Training, Inc., Keynote Speakers at Anti-Aging and …

Posted: Published on September 26th, 2013

Miami (PRWEB) September 25, 2013 Two specialists from Stem Cell Training, Inc., a division of the Global Stem Cells Group, were invited keynote speakers at last months prestigious 7th annual World Meeting of the Australian Academy for Anti-Aging Medicine in Melbourne, Australia. Joseph Purita, M.D. and Maritza Novas R.N., M.S.N., were in Melbourne August 24th and 25th for the two-day conference, focusing their discussions on stem cell medicine and its anti-aging applications. Purita and Novas joined other leaders from the worlds medical community to share cutting edge research and techniques from multiple medical streams to present groundbreaking advances in evidence-based, best-practice protocols for the early detection, prevention and treatment of obesity, metabolic disorders, related diseases and premature decline. Purita, a lead trainer for Stem Cell Training, Inc. and a pioneer in the use of stem cells in orthopedics, graduated from Georgetown University Medical School and has been with the Boca Raton Orthopedic Group since 1981. He is a Global Stem Cell Group Advisory Board member and a member of the following organizations: Purita is Board Certified by the following organizations: Novas received her Medical Degree from the Medical School of University of Havana, completed her post-doctoral training and residency program … Continue reading

Comments Off on Joseph Purita, M.D. and Maritza Novas, R.N., M.S.N of Stem Cell Training, Inc., Keynote Speakers at Anti-Aging and …

Study of 'sister' stem cells uncovers new cancer clue

Posted: Published on September 26th, 2013

Public release date: 26-Sep-2013 [ | E-mail | Share ] Contact: Graham Shaw graham.shaw@icr.ac.uk 44-020-715-35380 Institute of Cancer Research Scientists have used a brand new technique for examining individual stem cells to uncover dramatic differences in the gene expression levels which genes are turned 'up' or 'down' between apparently identical 'sister' pairs. The research, published today (Thursday) in Stem Cell Reports, was conducted and funded by The Institute of Cancer Research, London. It provides the latest evidence that despite having identical DNA, sister stem cells can display considerable differences in their molecular characteristics. The study showed that DNA methylation, a process that controls which genes are expressed in cells, plays an important role in generating non-genetic (or 'epigenetic') differences between sister cells. DNA methylation could therefore be one of the reasons for the major molecular variation between different cancer cells in the same tumour and drugs to reduce methylation might help control variation and make cancers easier to treat. In the new research, scientists at The Institute of Cancer Research (ICR) developed a novel micro-dissection technique to separate pairs of sister embryonic stem cells for single cell RNA analysis [1]. Using their new high-tech method, researchers separated and isolated mouse … Continue reading

Comments Off on Study of 'sister' stem cells uncovers new cancer clue

Stem Cell Scientists Identify Key Regulator Controlling Formation of Blood-Forming Stem Cells

Posted: Published on September 26th, 2013

Newswise (TORONTO, Canada Sept. 26, 2013) Stem cell scientists have moved one step closer to producing blood-forming stem cells in a Petri dish by identifying a key regulator controlling their formation in the early embryo, shows research published online today in Cell. The work was reported by Dr. Gordon Keller, Director of the McEwen Centre for Regenerative Medicine, and Senior Scientist at Princess Margaret Cancer Centre, both at University Health Network. Dr. Keller is also Professor in the Department of Medical Biophysics at the University of Toronto and holds a Canada Research Chair in stem cell biology. Using mouse models to study the process of blood cell development, Dr. Keller and his team demonstrated that the retinoic acid signalling pathway is required for formation of blood-forming stem cells. Retinoic acid is produced from vitamin A and is essential for many areas of human growth and development. When the researchers genetically disrupted the pathway that produces retinoic acid in mice, no blood-forming stem cells were produced. When they activated the pathway at the precise stage when stem cells develop, they observed a large increase in the number of blood-forming stem cells. Understanding how different cells and tissues are made in the … Continue reading

Comments Off on Stem Cell Scientists Identify Key Regulator Controlling Formation of Blood-Forming Stem Cells

Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase …

Posted: Published on September 26th, 2013

CAMBRIDGE, MA--(Marketwired - Sep 26, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 96 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results through nearly two years showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test (6MWT). As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at Week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes. After 96 weeks, patients in the 30 mg/kg and 50 mg/kg eteplirsen cohorts who were able to perform the 6MWT (modified Intent-to-Treat or mITT population; n=6) experienced less than a 5 percent decline (17.5 meters) from baseline in walking ability. A statistically significant treatment benefit of 70.8 meters (p 0.001) was observed for the mITT population compared with the placebo/delayed-treatment cohort (n=4), which initiated treatment at Week 25 following 24 weeks of placebo. After experiencing a substantial decline earlier in the study, the placebo/delayed-treatment cohort also demonstrated stabilization in walking ability from Week 36 through … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase …

“CureDuchenne Ventures” Launched to Accelerate Drug Discovery and Development for Duchenne Muscular Dystrophy

Posted: Published on September 26th, 2013

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- CureDuchenne announced today the launch of CureDuchenne Ventures, a new initiative to identify and develop a robust pipeline of therapies to treat Duchenne, the most common and lethal form of muscular dystrophy. This drug discovery and development initiative is based on CureDuchennes successful venture philanthropy model, in which the organization provides early stage funding to biotechnology, pharmaceutical companies and academic investigators to help develop breakthrough therapies to treat Duchenne. Were launching CureDuchenne Ventures at an exciting time in Duchenne research, said Debra Miller, CEO and Founder of CureDuchenne. Duchenne is a progressive disease and currently there is no treatment or cure, so our goal is to accelerate research that could benefit this generation of Duchenne boys. CureDuchenne Ventures will focus on venture philanthropists, foundations, and donors with an interest in scientific research for rare diseases, such as Duchenne. The first research project to be funded through CureDuchenne Ventures is a collaboration with biopharmaceutical company, Lexicon Pharmaceuticals (Woodlands, TX). Lexicons experimental drug, LX2931, which is in clinical development as a potential treatment of rheumatoid arthritis and autoimmune disease, is currently being evaluated for its potential to initiate muscle regeneration in studies with the mdx mouse model of … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on “CureDuchenne Ventures” Launched to Accelerate Drug Discovery and Development for Duchenne Muscular Dystrophy

New Recommendations on Treatments for Seizures in Autism

Posted: Published on September 26th, 2013

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? … Continue reading

Comments Off on New Recommendations on Treatments for Seizures in Autism

Autism parents group holding conference in Madison

Posted: Published on September 26th, 2013

As a baby, Luke Stuhleys speech was delayed. When he started talking, he mostly repeated what others said. Just before he turned 2, he stopped making eye contact. A few months later came the diagnosis: autism. It was devastating, said Kate Whelan, Lukes mother. I was pretty lost. You get the diagnosis and youre just left to flail. Whelan, of McFarland, eventually found other patents with autistic children who pointed her to treatments and programs. Now shes co-coordinator of the Wisconsin chapter of Talk About Curing Autism, or TACA, a national group that helps families affected by autism. TACA is holding a conference in Madison Friday and Saturday on topics ranging from experimental tests for autism to preparing older children with the condition to live on their own. There are things you can do as parents, said Lisa Ackerman, who founded TACA in 2000 after feeling that some groups were too negative in their approach. There are positive steps you can take. The cause of autism, a developmental disability that alters social interaction and communication, largely remains a mystery. It could involve a combination of genetic, biologic and environmental factors, scientists say. A federal survey of parents released in March … Continue reading

Comments Off on Autism parents group holding conference in Madison

McDowell makes strides in helping stroke victims

Posted: Published on September 26th, 2013

Ephraim McDowell Regional Medical Center now has a new process when it comes to treating stroke patients. Stroke is the fourth leading cause of death in the United States and the leading cause of disability for adults. However, with prompt medical treatment, patient outcomes can be drastically improved. The hospitals emergency department and local emergency medical services have implemented a system that is called Stroke Alert. When EMS picks up a patient they believe is having a stroke, the hospital is notified before the patient arrives and issues a Stroke Alert. Upon arrival at the hospital, the patient is met at the ambulance by the stroke team, which consists of an emergency department physician, charge nurse, staff nurse, tech, laboratory tech and pharmacist. The team immediately takes the patient from the ambulance to the CT scanner for a scan of the head while each team member performs essential assessments and testing. The CT scan results determine if the patient has had a stroke, and then the stroke team determines the best treatment option. The most effective form of treatment available, IV t-PA (a medication used that dissolves blood clots), must be administered within four hours of the time that the … Continue reading

Comments Off on McDowell makes strides in helping stroke victims

Heart and Stroke commits $25 million in funding to University of Calgary

Posted: Published on September 26th, 2013

CALGARY, ALBERTA--(Marketwired - Sep 26, 2013) - As one of 19 university and hospital partners across Canada conducting leading heart and stroke research, the University of Calgary will receive a minimum of $25 million for research projects over the next 10 years. This is part of the $300-million funding announcement made by the Heart and Stroke Foundation of Canada in June. "The University of Calgary is honoured to be among this esteemed group chosen to be part of the Heart and Stroke Foundation Research Leadership Circle," says Elizabeth Cannon, president of the University of Calgary. "The Heart and Stroke Foundation's long-term funding commitment benefits our research through a greater ability to plan our programming, to recruit and retain expertise, and to collaborate on research that contributes to the prevention, diagnosis and treatment of heart disease and stroke." "We are delighted to enhance our partnership with Heart and Stroke," says Dr. Todd Anderson, a clinician-researcher at the University of Calgary and director of the Libin Cardiovascular Institute of Alberta. "Research support from the Foundation will enable University of Calgary researchers and our collaborators across the country to make even greater contributions to the prevention, diagnosis and treatment of heart disease and … Continue reading

Comments Off on Heart and Stroke commits $25 million in funding to University of Calgary

Page 4,883«..1020..4,8824,8834,8844,885..4,8904,900..»